. Author manuscript; available in PMC: 2020 Dec 1.

Published in final edited form as: Nat Biomed Eng. 2020 Jun 1;4(6):636–648. doi: 10.1038/s41551-020-0563-4

Table 1 –

Overview of the pharmacokinetic determinants of vaccine immunogenicity

	1. Size Exclusion from Systemic Absorption			2. Proteolytic Stability	3. Avoidance of Distal Priming	Immunogenicity
Quantity	MW(kDa)	Radius (nm)	k_abs (hr⁻¹) (fit data ± SE)	% Serum-treated antigen recall response relative to fresh	k_clear(hr⁻¹) (fit data ± SE)	Vaccine Response (% of CD8+ T Cells) (wean ± SD)
E7_38–57 Peptide	2.2	-	1.37 + 0.40	21.5%	0.55 + 0.11	0.12 + 0.07
FC-E7_38–57	57.8	3.4	0.13 + 0.02	59.3%	0.006 + 0.002	1.94 + 0.69
MSA-E7_38–57	69.4	3.3	0.14 ± 0.03	114%	0.019 ± 0.004	5.94 ± 1.38
TTR-E7_38–57	68.5	3.5	0.16 ± 0.03	61.0%	0.059 ± 0.006	12.45 ± 4.70